The Definition of Recurrence of Differentiated Thyroid Cancer: A Systematic Review of the Literature.


Journal

Thyroid : official journal of the American Thyroid Association
ISSN: 1557-9077
Titre abrégé: Thyroid
Pays: United States
ID NLM: 9104317

Informations de publication

Date de publication:
16 Sep 2024
Historique:
medline: 17 9 2024
pubmed: 17 9 2024
entrez: 16 9 2024
Statut: aheadofprint

Résumé

Background Recurrence is a key outcome to evaluate treatment effect of differentiated thyroid carcinoma (DTC). However, no consistent definition of recurrence is available in current literature or international guidelines. Therefore, the primary aim of this systematic review was to delineate the definitions of recurrence of DTC, categorized by total thyroidectomy with radioactive iodine ablation (RAI), total thyroidectomy without RAI and lobectomy, to assess if there is a generally accepted definition among these categories. Methods This study adhered to 2020 PRISMA statement. In December 2023, systematic literature search in MEDLINE and EMBASE was performed for studies reporting on recurrence of DTC, from January 2018 to December 2023. Studies that did not provide a definition were excluded. Primary outcome was the definition of recurrence of DTC. Secondary outcome whether studies differentiated between recurrence and persistent disease. Two independent investigators screened titles and abstracts, followed by full-text assessment and data extraction. The study protocol was registered in PROSPERO,CRD42021291753. Results In total, 1450 studies were identified. Seventy studies met inclusion criteria, including 69 retrospective studies and one RCT. Median number of patients in included studies was 438 (range 25 - 2297). Seventeen studies (24.3%) reported on lobectomy, four studies (5.7%) on total thyroidectomy without RAI, and 49 studies (70.0%) with RAI. All studies defined recurrence using one or a combination of four diagnostic modalities: cytology/pathology, imaging studies, thyroglobulin(-antibodies), predetermined minimum tumor-free time span. The most common definition of recurrence following lobectomy was cytology/pathology-proven recurrence (47.1% of this subgroup), following total thyroidectomy with RAI was cytology/pathology-proven recurrence and/or anomalies detected on imaging studies (22.4% of this subgroup). No consistent definition was found following total thyroidectomy without RAI. Nine studies (12.9%) differentiated between recurrence and persistent disease. Conclusion Our main finding is that there is no universally accepted definition for recurrence of DTC in the current studies across any of the treatment categories. The findings of this study will provide the basis for a future, international Delphi-based proposal to establish a universally accepted definition of recurrence of DTC. A uniform definition could facilitate global discussion and enhance the assessment of treatment outcomes regarding recurrence of DTC.

Identifiants

pubmed: 39283824
doi: 10.1089/thy.2024.0271
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Daniël Jacob van de Berg (DJ)

Emma Childrens' Hospital UMC, Pediatric Surgery, Amsterdam, North-Holland, Netherlands; d.j.vandeberg@amsterdamumc.nl.

Pedro Manuel Rodriguez Schaap (PM)

Amsterdam UMC, location VU University Medical Center, Surgery, De Boelelaan 1117, Amsterdam, Netherlands, 1081 HV.
Legmeerstraat66-2Mozambique; p.rodriguezschaap@amsterdamumc.nl.

Faridi S Jamaludin (FS)

Amsterdam UMC Location AMC, Medical Library, Amsterdam, North-Holland, Netherlands; f.s.vanetten@amsterdamumc.nl.

Hanneke M van Santen (HM)

University Hospital for Children and Youth 'Het Wilhelmina Kinderziekenhuis' University Medical Centre Utrecht, Pediatric Endocrinology, Lundlaan 5, Utrecht, Netherlands, 3508 AB.
Princess Maxima Center for Pediatric Oncology, Pediatric Endocrinology, Utrecht, Netherlands, 3720 AC; h.m.vansanten@umcutrecht.nl.

Sarah C Clement (SC)

Wilhelmina Children's Hospital University Medical Centre, Pediatric Endocrinology, Utrecht, Utrecht, Netherlands; s.c.clement-2@umcutrecht.nl.

Menno R Vriens (MR)

Umcu, Surgery, Heidelberglaan 100, Utrecht, Netherlands, 3584CX; mvriens@umcutrecht.nl.

A S Paul van Trotsenburg (ASP)

Emma Childrens Hospital AMC, Meibergdreef 9, Amsterdam, Netherlands, 1100 DD.
United States; a.s.vantrotsenburg@amsterdamumc.nl.

Christiaan F Mooij (CF)

Amsterdam UMC, Pediatric Endocrinology, Meibergdreef 9, Amsterdam, Netherlands, 1105 AZ; c.mooij@amsterdamumc.nl.

Eveline Bruinstroop (E)

Amsterdam UMC Location AMC, Endocrinology, Amsterdam, North-Holland, Netherlands; e.bruinstroop@amsterdamumc.nl.

Schelto Kruijff (S)

UMCG , Surgical oncology and endocrinology, Groningen, Netherlands.
Karolinska Institutet, Molecular Medicine and Surgery, Stockholm, Stockholm, Sweden; s.kruijff@umcg.nl.

Robin P Peeters (RP)

Erasmus MC, Dept of Internal Medicine, Dept of Endocrinology, 's Gravendijkwal 230, Room H555, Rotterdam, Netherlands, 3015CE; r.peeters@erasmusmc.nl.

Frederik A Verburg (FA)

Erasmus Medical Center, Department of Radiology and Nuclear Medicine, Rotterdam, Zuid-Holland, Netherlands; f.verburg@erasmusmc.nl.

Romana Netea-Maier (R)

Radboud University Nijmegen Medical Centre, Department of Medicine, Division of Endocrinology, Nijmegen, Netherlands.
Iuliu Hagieganu University of Medicine and Pharmacy Faculty of Medicine, Research Center for Functional Genomics, Biomedicine and Translation Medicine, Cluj Napoca, Romania; Romana.Netea-Maier@radboudumc.nl.

Els J M Nieveen van Dijkum (EJM)

Amsterdam University Medical Centres, Surgery, Cancer Center Amsterdam, Amsterdam, Noord-Holland, Netherlands; e.j.nieveenvandijkum@amsterdamumc.nl.

Joep P M Derikx (JPM)

Emma Childrens' Hospital UMC, Pediatric Surgery, Amsterdam, Noord-Holland, Netherlands; j.derikx@amsterdamumc.nl.

Anton F Engelsman (AF)

Amsterdam UMC - Locatie VUMC, Surgery, de Boelelaan 1117, Amsterdam, Noord-Holland, Netherlands, 1081HV; a.f.engelsman@amsterdamumc.nl.

Classifications MeSH